References
- Balogova S, Huchet V, Kerrou K, et al (2010). Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun, 31, 389-97.
- Changlai SP, Tsai SC, Chou MC, et al (2001). Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep, 8, 337-9.
- Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
- Demura Y, Tsuchida T, Ishizaki T, et al (2003). 18F-FDG accumulation with PET for differentiation between benign and malignant nodules in the thorax. J Nucl Med, 44, 540-8.
- Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
- Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
- Hou ZB, Lu KJ, Wu XL, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment.Asian Pac J Cancer Prev, 15, 1767-9 https://doi.org/10.7314/APJCP.2014.15.4.1767
- Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
- Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
- Kaira K, Yamamoto N, Endo M, et al (2014). 18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. Oncol Rep, 31, 209-215.
- Lee TS, Ahn SH, Moon BS, et al (2009). Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol, 36, 681-686. https://doi.org/10.1016/j.nucmedbio.2009.03.009
- Liu FL, Hong QY, Shi HC, et al (2013). Value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in early diagnosis of lung cancer.Zhonghua Yi Xue Za Zhi, 93, 3019-22.
- Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
- Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
-
Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection (
$Yadanzi^{(R)}$ ) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791 - Minamimoto R, Senda M, Jinnouchi S, et al (2014). Detection of lung cancer by FDG-PET cancer screening program: a nationwide Japanese survey. Anticancer Res, 34, 183-9.
- Shreve PD, Anzai Y, Wahl RL (1999). Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics, 19, 61-77. https://doi.org/10.1148/radiographics.19.1.g99ja0761
- Wang ZX, Zhang B, Wu YW, et al (2011). The clinic value of (18)F-FDG PET/CT imaging in differentiation of malignant from benign disease in lung. Zhonghua Yi Xue Za Zhi, 91, 2456-8.
- Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801